Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELEV Elevation Oncology	$0.37	$0.36	$0.22 ▼ $3.09	$21.62M	1.48	1.18 million shs	N/A
KTTA Pasithea Therapeutics	$0.70 -3.7%	$0.78	$0.65 ▼ $7.50	$5.40M	0.25	123,159 shs	76,724 shs
PASG Passage Bio	$5.74 -10.6%	$7.54	$5.12 ▼ $26.60	$20.03M	1.81	104,930 shs	48,930 shs
VYNE VYNE Therapeutics	$0.35 -3.5%	$1.14	$0.34 ▼ $4.30	$5.56M	1.76	2.79 million shs	2.94 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELEV Elevation Oncology	0.00%	0.00%	-3.62%	+4.29%	-86.12%
KTTA Pasithea Therapeutics	-4.36%	-3.83%	-6.63%	-50.13%	-86.70%
PASG Passage Bio	-10.59%	-22.85%	-29.36%	-27.34%	-67.75%
VYNE VYNE Therapeutics	-3.47%	-75.83%	-76.63%	-74.24%	-81.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELEV Elevation Oncology	2.7444 of 5 stars	3.0	5.0	2.2	1.7	0.6
KTTA Pasithea Therapeutics	0.699 of 5 stars	0.0	5.0	0.0	0.8	0.6
PASG Passage Bio	3.8267 of 5 stars	3.5	5.0	3.3	2.5	1.3
VYNE VYNE Therapeutics	2.5343 of 5 stars	3.0	5.0	1.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELEV Elevation Oncology	2.00	Hold	$3.39	827.59% Upside
KTTA Pasithea Therapeutics	0.00	N/A	N/A	N/A
PASG Passage Bio	3.00	Buy	$150.00	2,513.24% Upside
VYNE VYNE Therapeutics	2.00	Hold	$6.25	1,671.04% Upside

Current Analyst Ratings Breakdown

Latest KTTA, VYNE, PASG, and ELEV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2025	VYNE VYNE Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/30/2025	VYNE VYNE Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/30/2025	VYNE VYNE Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
6/24/2025	PASG Passage Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$120.00
6/10/2025	ELEV Elevation Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/10/2025	ELEV Elevation Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral
6/9/2025	ELEV Elevation Oncology	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/9/2025	ELEV Elevation Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	$1.02 per share	N/A
KTTA Pasithea Therapeutics	N/A	N/A	N/A	N/A	$10.60 per share	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	$19.84 per share	N/A
VYNE VYNE Therapeutics	$500K	10.74	N/A	N/A	$3.53 per share	0.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELEV Elevation Oncology	-$44.49M	-$0.82	N/A	N/A	N/A	N/A	-74.68%	-48.14%	8/5/2025 (Estimated)
KTTA Pasithea Therapeutics	-$13.90M	-$10.60	N/A	∞	N/A	N/A	-88.14%	-81.21%	8/12/2025 (Estimated)
PASG Passage Bio	-$64.77M	-$20.40	N/A	N/A	N/A	N/A	-93.59%	-59.65%	8/14/2025 (Estimated)
VYNE VYNE Therapeutics	-$39.83M	-$0.99	N/A	N/A	N/A	-6,974.55%	-71.89%	-58.94%	8/13/2025 (Estimated)

Latest KTTA, VYNE, PASG, and ELEV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PASG Passage Bio	-$0.20	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	VYNE VYNE Therapeutics	-$0.24	N/A	N/A	N/A	$0.15 million	N/A
8/5/2025	Q2 2025	ELEV Elevation Oncology	-$0.26	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	ELEV Elevation Oncology	-$0.20	-$0.24	-$0.04	-$0.24	N/A	N/A
5/15/2025	Q1 2025	KTTA Pasithea Therapeutics	N/A	-$1.61	N/A	-$1.61	N/A	N/A
5/13/2025	Q1 2025	PASG Passage Bio	-$4.80	-$5.00	-$0.20	-$0.25	N/A	N/A
5/8/2025	Q1 2025	VYNE VYNE Therapeutics	-$0.29	-$0.20	+$0.09	-$0.20	$0.05 million	$0.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	N/A
KTTA Pasithea Therapeutics	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELEV Elevation Oncology	0.67	19.40	19.40
KTTA Pasithea Therapeutics	N/A	3.84	3.84
PASG Passage Bio	N/A	3.74	3.74
VYNE VYNE Therapeutics	N/A	4.47	4.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELEV Elevation Oncology	83.70%
KTTA Pasithea Therapeutics	23.92%
PASG Passage Bio	53.48%
VYNE VYNE Therapeutics	83.78%

Insider Ownership

Company	Insider Ownership
ELEV Elevation Oncology	8.10%
KTTA Pasithea Therapeutics	2.70%
PASG Passage Bio	5.00%
VYNE VYNE Therapeutics	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELEV Elevation Oncology	40	59.22 million	54.43 million	Optionable
KTTA Pasithea Therapeutics	3	7.44 million	7.24 million	Not Optionable
PASG Passage Bio	130	3.12 million	2.96 million	Optionable
VYNE VYNE Therapeutics	30	15.21 million	14.48 million	Not Optionable

KTTA, VYNE, PASG, and ELEV Headlines

Recent News About These Companies

VYNE Therapeutics (NASDAQ:VYNE) Lowered to "Neutral" Rating by HC Wainwright

August 2 at 2:15 AM | americanbankingnews.com

Here's Why VYNE Therapeutics (NASDAQ:VYNE) Must Use Its Cash Wisely

August 1 at 4:19 AM | finance.yahoo.com

Repibresib gel fails to meet endpoints for nonsegmental vitiligo study

August 1 at 4:19 AM | healio.comH

Vyne Therapeutics Ends Trial of Repibresib Gel in Nonsegmental Vitiligo

July 31 at 3:02 AM | marketwatch.com

VYNE Therapeutics stock falls after vitiligo trial fails to meet endpoints

July 31 at 3:02 AM | za.investing.com

HC Wainwright & Co. Downgrades VYNE Therapeutics (VYNE)

July 31 at 3:02 AM | msn.com

VYNE Ends Phase IIb Vitiligo Trial of Repibresib After Missing Primary Endpoint

July 31 at 3:02 AM | appliedclinicaltrialsonline.comA

VYNE Therapeutics Shares Sink Premarket Following End to Trial After Endpoint Missed

July 31 at 3:02 AM | marketwatch.com

Vyne's lead BET inhibitor fails phase 2 vitiligo trial, sinking stock

July 31 at 3:02 AM | fiercebiotech.comF

Vyne Hit With Downgrades After Repibresib Misses Endpoints In Vitiligo Trial; Traders Still Eye Rebound

July 31 at 3:02 AM | msn.com

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

July 30 at 8:00 AM | globenewswire.com

VYNE Therapeutics (NASDAQ:VYNE) Shares Down 0.7% - Here's What Happened

July 30 at 2:39 AM | americanbankingnews.com

Vyne Therapeutics: A Risky Bet On Upcoming Vitiligo Ph2b Readout

July 28, 2025 | seekingalpha.com

VYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline Progress

July 11, 2025 | insidermonkey.com

Vyne prunes psoriasis trial under FDA hold, but keeps faith in BET inhibitor

July 2, 2025 | fiercebiotech.comF

VYNE Therapeutics Provides Update on VYN202 Program Following FDA Clinical Hold for Psoriasis Trial

July 2, 2025 | quiverquant.comQ

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

July 2, 2025 | globenewswire.com

VYNE Stock Touches 52-Week Low at $0.96 Amid Market Challenges

May 31, 2025 | investing.com

VYNE Therapeutics First Quarter 2025 Earnings: Beats Expectations

May 12, 2025 | finance.yahoo.com

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

May 8, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA, VYNE, PASG, and ELEV Company Descriptions

Elevation Oncology NASDAQ:ELEV

$0.36 0.00 (0.00%)

As of 07/23/2025

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

Pasithea Therapeutics NASDAQ:KTTA

$0.70 -0.03 (-3.71%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$0.69 -0.01 (-1.03%)

As of 08/1/2025 07:44 PM Eastern

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Passage Bio NASDAQ:PASG

$5.74 -0.68 (-10.59%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$5.86 +0.12 (+2.00%)

As of 08/1/2025 07:28 PM Eastern

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

VYNE Therapeutics NASDAQ:VYNE

$0.35 -0.01 (-3.47%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$0.36 +0.00 (+0.60%)

As of 08/1/2025 07:58 PM Eastern

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time